Emergent BioSolutions to supply $1 billion of Anthrax vaccine to US Strategic National Stockpile

Maryland based biopharmaceutical company Emergent BioSolutions Inc has signed a contract to supply the US Government with almost $1 billion worth of anthrax vaccines.

Emergent BioSolutions announced that the US Department of Health and Human Services (HHS) is progressing its anthrax preparedness strategy with multiple contracts for the company’s anthrax vaccines.

Emergent has signed a follow-on contract with the Centers for Disease Control and Prevention (CDC) valued at up to $911 million to supply approximately 29.4 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS) by September 2021. BioThrax is the only anthrax vaccine licensed by the US Food and Drug Administration (FDA) and is indicated for both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease.

Read more